199 related articles for article (PubMed ID: 38073715)
1. Stereotactic ablative radiotherapy for primary renal cell carcinoma.
Yang DX; Kwon YS; Timmerman R; Hannan R
Clin Transl Radiat Oncol; 2024 Jan; 44():100705. PubMed ID: 38073715
[TBL] [Abstract][Full Text] [Related]
2. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
[TBL] [Abstract][Full Text] [Related]
3. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
[TBL] [Abstract][Full Text] [Related]
4. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
Rühle A; Andratschke N; Siva S; Guckenberger M
Clin Transl Radiat Oncol; 2019 Sep; 18():104-112. PubMed ID: 31341985
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy for primary renal cell carcinoma: A review on behalf of the CC-AFU.
Bentahila R; Bensalah K; Benziane-Ouaritini N; Barthelemy P; Rioux-Leclerc N; Correas JM; Belhomme S; Bigot P; Sargos P
Fr J Urol; 2024 May; 34(7-8):102660. PubMed ID: 38823486
[TBL] [Abstract][Full Text] [Related]
7. The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma.
Cheung P; Thibault I; Bjarnason GA
Curr Opin Support Palliat Care; 2014 Sep; 8(3):258-64. PubMed ID: 25090288
[TBL] [Abstract][Full Text] [Related]
8. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
9. First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer.
Zarkar A; Henderson D; Carver A; Heyes G; Harrop V; Tutill S; Kilkenny J; Marshall A; Elbeltagi N; Howard H
BJUI Compass; 2023 Jul; 4(4):464-472. PubMed ID: 37334027
[TBL] [Abstract][Full Text] [Related]
10. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
12. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Role of Radiation Therapy in Renal Cell Carcinoma.
Christensen M; Hannan R
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230615
[TBL] [Abstract][Full Text] [Related]
14. The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma.
Barbour AB; Kirste S; Grosu AL; Siva S; Louie AV; Onishi H; Swaminath A; Teh BS; Psutka SP; Weg ES; Chen JJ; Zeng J; Gore JL; Hall E; Liao JJ; Correa RJM; Lo SS
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509333
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
[TBL] [Abstract][Full Text] [Related]
17. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
18. The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review.
Wei Q; He H; Lv L; Xu X; Sun W
Transl Androl Urol; 2020 Dec; 9(6):2821-2830. PubMed ID: 33457253
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract][Full Text] [Related]
20. SABR for oligometastatic renal cell carcinoma.
David C; Muhammad A; Cristian U; Ben T; Arun A; Lewis A; Lavinia S; Marlon P; Shankar S
Clin Transl Radiat Oncol; 2024 Mar; 45():100739. PubMed ID: 38380117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
